Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative

symbol logo$LENZ Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.99 down -67.80% YoY • Reported revenue of $3.38M down -72.96% YoY • LENZ Therapeutics expects the reorganization to reduce projected 2027 annualized operating expenses by more than 50%, targeting approximately $70M to $75M, excluding stock-based compensation.
1
5

Price since post

Full Details
Tomx24
This AI-generated bull/bear recap completely misses the point. Comparing 2025 licensing revenue with 2026 launch sales is apples to oranges, not meaningful analysis. VIZZ product sales grew 50% QoQ, paid prescriptions rose 51%, and consumer activation is clearly working. With 15,000+ prescribers and over 75% prescribing repeatedly, cutting an oversized physician-focused salesforce is strategic correction, not a bearish signal. The real failure was prioritizing gatekeeper awareness over consumer demand from day one. The CEO change and restructuring reflect that mistake. The question now is whether LENZ can scale consumer acquisition efficiently. Neither the bull nor the bear case addresses this.

Advertisement|Remove ads.